Interest Archives - Page 46 of 58 - Food and Drug Law Institute (FDLI)

DEA Preregistration and Cyclic Inspections: What Applicants and Registrants Must Know in the Prescription Opioid Epidemic Age
Gallery
DEA Preregistration and Cyclic Inspections: What Applicants and Registrants Must Know in the Prescription Opioid Epidemic Age

Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update November/December 2017

DEA Preregistration and Cyclic Inspections: What Applicants and Registrants Must Know in the Prescription Opioid Epidemic Age

Update Magazine | November/December 2017

DEA Preregistration and Cyclic Inspections: What Applicants and Registrants Must Know in the Prescription Opioid Epidemic Ageadmin2018-06-26T13:16:41-04:00

Real World Evidence: Data Requirements, Utilization, and Presentation
Gallery
Real World Evidence: Data Requirements, Utilization, and Presentation

Drugs, Medical Devices, Biologics, Event, Medical Products Webinars, On-demand Webinar

Real World Evidence: Data Requirements, Utilization, and Presentation

Recorded December 1, 2017 | On-Demand Webinar

Real World Evidence: Data Requirements, Utilization, and Presentationadmin2024-07-19T09:50:36-04:00

Capturing Postmarket Benefits in Device Compliance and Enforcement
Gallery
Capturing Postmarket Benefits in Device Compliance and Enforcement

Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update November/December 2017

Capturing Postmarket Benefits in Device Compliance and Enforcement

Update Magazine | November/December 2017

Capturing Postmarket Benefits in Device Compliance and Enforcementadmin2018-06-26T13:16:42-04:00

Those Involved in Compound Pharmaceuticals Beware: Law Enforcement Is Focused on You
Gallery
Those Involved in Compound Pharmaceuticals Beware: Law Enforcement Is Focused on You

Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update November/December 2017

Those Involved in Compound Pharmaceuticals Beware: Law Enforcement Is Focused on You

Update Magazine | November/December 2017

Those Involved in Compound Pharmaceuticals Beware: Law Enforcement Is Focused on Youadmin2018-06-26T13:16:43-04:00

Kid Tested, FDA Approved: Examining Pediatric Drug Testing
Gallery
Kid Tested, FDA Approved: Examining Pediatric Drug Testing

Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Publications, Volume 72.4

Kid Tested, FDA Approved: Examining Pediatric Drug Testing

Food and Drug Law Journal | Volume 72 | Number 4

Kid Tested, FDA Approved: Examining Pediatric Drug Testingadmin2021-04-21T15:51:39-04:00

Get Real: Organic Marketing Under USDA’s Proposed Promotion & Research Agreement
Gallery
Get Real: Organic Marketing Under USDA’s Proposed Promotion & Research Agreement

Archived Publication, Food and Drug Law Journal, Food, Dietary Supplements, Cosmetics, Publications, Volume 72.4

Get Real: Organic Marketing Under USDA’s Proposed Promotion & Research Agreement

Food and Drug Law Journal | Volume 72 | Number 4

Get Real: Organic Marketing Under USDA’s Proposed Promotion & Research Agreementadmin2021-04-21T15:57:02-04:00

What Happens When FDA Delays a Rule? Menu Labeling as a Case Study
Gallery
What Happens When FDA Delays a Rule? Menu Labeling as a Case Study

Archived Publication, Food, Dietary Supplements, Cosmetics, Publications, Update Magazine, Update November/December 2017

What Happens When FDA Delays a Rule? Menu Labeling as a Case Study

Update Magazine | November/December 2017

What Happens When FDA Delays a Rule? Menu Labeling as a Case Studyadmin2018-06-26T13:16:43-04:00

When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA
Gallery
When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA

Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Publications, Volume 72.4

When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDA

Food and Drug Law Journal | Volume 72 | Number 4

When the Alpha is the Omega: P-Values, “Substantial Evidence,” and the 0.05 Standard at FDAadmin2021-04-21T15:59:31-04:00

The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls
Gallery
The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls

Archived Publication, Drugs, Medical Devices, Biologics, Publications, Update Magazine, Update November/December 2017

The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls

Update Magazine | September/October 2017

The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfallsadmin2018-06-26T13:16:44-04:00

Brand Name Preemption: The New Frontier In Pharmaceutical Product Liability Litigation
Gallery
Brand Name Preemption: The New Frontier In Pharmaceutical Product Liability Litigation

Archived Publication, Drugs, Medical Devices, Biologics, Food and Drug Law Journal, Publications, Volume 72.4

Brand Name Preemption: The New Frontier In Pharmaceutical Product Liability Litigation

Food and Drug Law Journal | Volume 72 | Number 4

Brand Name Preemption: The New Frontier In Pharmaceutical Product Liability Litigationadmin2021-04-21T16:10:23-04:00